Advanced Biomarker Assessment in Pelvic Organ Prolapse
| Status: | Recruiting |
|---|---|
| Conditions: | Women's Studies |
| Therapuetic Areas: | Reproductive |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/27/2018 |
| Start Date: | June 29, 2018 |
| End Date: | March 22, 2019 |
Advanced Biomarker Assessment of Adipose Derived Stem Cells and Fibroblasts in Patients With and Without Pelvic Organ Prolapse
This study will assess advanced biomarkers in patients with and without vaginal prolapse.
Assessments will be directed at vaginal fibroblasts and adipose derived stem cells.
Assessments will be directed at vaginal fibroblasts and adipose derived stem cells.
Vaginal biopsies and abdominal adipose harvest will be accomplished in patients undergoing
vaginal hysterectomy for non-prolapse benign conditions (6) and pelvic organ prolapse (6).
Samples of tissues will be divided and portions will be snap-frozen, placed into transport
medium for subsequent tissue digestion, and receive paraffin processing. Cells in transport
medium will be transported to the Mayo Collaborative Research building (lab of Dr. David
Lott) for isolation of fibroblasts and adipose derived stem cells.
The other samples will be transported to the lab of Dr. Andre van Wijnen (RST) to isolate RNA
and protein for mRNA, microRNA and additional protein analysis.
Isolated fibroblasts and ASC's from the lab of Dr. Lott (MCA) will be expanded and passaged
3-5 times. ASCs phenotype will be confirmed by flow cytometry. Cells lines will be duplicated
and biobanked at the Mayo Clinic Rochester Biotrust and separately biobanked at the Arizona
State University lab of scaffold collaborator, Dr. Stephen Massia. Additional frozen cell
lines will transported to the lab of Dr. Andre van Wijnen for further processing. . All cells
and materials will be used for testing and to advance the science of regenerative medicine.
No biobanked cells or materials from this specific project will be used for any future
intervention or treatment in humans.
vaginal hysterectomy for non-prolapse benign conditions (6) and pelvic organ prolapse (6).
Samples of tissues will be divided and portions will be snap-frozen, placed into transport
medium for subsequent tissue digestion, and receive paraffin processing. Cells in transport
medium will be transported to the Mayo Collaborative Research building (lab of Dr. David
Lott) for isolation of fibroblasts and adipose derived stem cells.
The other samples will be transported to the lab of Dr. Andre van Wijnen (RST) to isolate RNA
and protein for mRNA, microRNA and additional protein analysis.
Isolated fibroblasts and ASC's from the lab of Dr. Lott (MCA) will be expanded and passaged
3-5 times. ASCs phenotype will be confirmed by flow cytometry. Cells lines will be duplicated
and biobanked at the Mayo Clinic Rochester Biotrust and separately biobanked at the Arizona
State University lab of scaffold collaborator, Dr. Stephen Massia. Additional frozen cell
lines will transported to the lab of Dr. Andre van Wijnen for further processing. . All cells
and materials will be used for testing and to advance the science of regenerative medicine.
No biobanked cells or materials from this specific project will be used for any future
intervention or treatment in humans.
Inclusion Criteria-
- Patients undergoing vaginal hysterectomy for non-prolapse benign conditions and pelvic
organ prolapse
- at least 18 years old
- Mayo Clinic patient
Exclusion Criteria-
°Patients who have a history of a recognized classic connective tissue disease
We found this trial at
1
site
Click here to add this to my saved trials
